Press Release Archive
15 May 2012
Antares Pharma appoints LeRoux Jooste Senior Vice President of Pharmaceutical Sales and Marketing
10 May 2012
Antares Pharma to Present at the 15th Annual Bank of America Merrill Lynch Health Care Conference
8 May 2012
Antares Q1 2012 Earnings Results
1 May 2012
Antares Pharma Announces Q1 2012 Earnings
26 April 2012
Antares Pharma Announces Epinephrine AutoInjector Settlement Agreement Between Teva and Pfizer
26 April 2012
Watson Launches Gelnique 3
28 March 2012
Antares Pharma To Present At The 11th Annual Needham Healthcare Conference
12 March 2012
Antares Pharma Reports Fourth Quarter and Full Year 2011 Financial and Operating Results
5 March 2012
Antares Pharma to host 4th Quarter Earnings Call
29 February 2012
Antares Pharma to Present at Upcoming Investor Conferences Cowen and Roth
27 February 2012
Antares Pharma Appoints John J Howarth Vice President of Corporate Affairs
16 January 2012
Antares Pharma Enters Licensing Agreement with Daewoong Pharmaceuticals Co LTD
20 December 2011
Antares Pharma Enters Licensing Agreement with Pfizer Consumer Healthcare
12 December 2011
Antares Pharma to Present at the Oppenheimer 22nd Annual Healthcare Conference
8 December 2011
Antares Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
29 November 2011
Antares Pharma Announces Issuance of New Libigel Patent
8 November 2011
Antares Q3 2011 Earnings
1 November 2011
AIS 3Q Earnings Call Announcement
4 October 2011
Antares Pharma Granted New US Patent Covering VIBEX Injector Technology
8 August 2011
Antares Pharma Reports Second Quarter 2011 Financial and Operating Results
4 August 2011
Antares Pharma Announces Positive Study Results with VIBEX MTX in Rheumatoid Arthritis Patients New Patent Application Filed
1 August 2011
Antares Pharma to Host Second Quarter 2011 Earnings Call
11 July 2011
Watson and Antares Announce Exclusive License Agreement for Antares Oxybutynin Gel Product Anturol
18 May 2011
Antares Pharma Announces Closing of Public Offering of Common Stock
18 May 2011
Closing Announcement
13 May 2011
Antares Pharma Announces Pricing of Public Offering of Common Stock
13 May 2011
Pricing Announcement
12 May 2011
Antares Pharma Announces Proposed Public Offering of Common Stock
9 May 2011
Antares Pharma Reports First Quarter 2011 Financial and Operating
Results
9 May 2011
Antares Pharma First Quarter 2011 Earnings Results
3 May 2011
Antares Pharma First Quarter Earnings Call Announcement
3 May 2011
Antares Pharma to Host First Quarter 2011 Earnings Call
8 April 2011
Antares Pharma Announces FDA Acceptance of Anturol
29 March 2011
Antares Pharma to Present at the 10th Annual Needham Healthcare Conference
14 March 2011
Antares Pharma Reports Fourth Quarter and Full Year 2010 Financial
and Operating Results
8 March 2011
Antares Pharma to Present at the Roth 23rd Annual OC Growth Stock Conference
7 March 2011
Antares Pharma to Host Fourth Quarter and Full Year 2010 Earnings Call
1 March 2011
Antares Pharma to Present at the 31st Annual Cowen Health Care Conference
14 February 2011
Antares Pharma Announces Receipt of NDA User Fee Waiver
14 February 2011
Receipt of NDA User Fee Waiver
1 February 2011
Antares Pharma Announces First Rheumatoid Arthritis Patient Dosed in
VIBEXtrade MTX Clinical Trial
12 January 2011
Antares Pharma to Initiate Clinical Trial of VIBEX
22 December 2010
Antares Pharma Announces Filing of New Drug Application for Anturol
for Overactive Bladder
22 December 2010
Antares Pharma Announces Filing of New Drug Application For Anturol For Overactive Bladder
19 November 2010
Antares Pharma Announces Next Generation of AutoInjector Design
19 November 2010
Antares Pharma Announces Next Generation of AutoInjector Design
10 November 2010
Antares Pharma Reports Third Quarter 2010 Financial and Operating
Results
3 November 2010
Antares Pharma to Host Third Quarter 2010 Earnings Call
3 November 2010
Antares Pharma Awarded Qualifying Therapeutic Discovery Project
Grants for Anturol
27 October 2010
Antares Pharma to Present at the 21st Annual Oppenheimer Conference
17 September 2010
Antares Pharma Announces Planned Departure of Senior Executive
12 August 2010
Antares Pharma Reports Second Quarter 2010 Financial and Operating
Results
4 August 2010
Antares Pharma to Host Second Quarter 2010 Earnings Call
29 July 2010
Antares Pharma to Present at the BMO 10th Annual Focus on Healthcare Conference
27 July 2010
Antares Pharma Announces Positive Top Line Results From Its Pivotal
Phase 3 Study of Anturol Gel for the Treatment of Overactive Bladder
28 June 2010
Antares Pharma added to Russell 3000 Index
19 May 2010
Antares Pharma Announces Receipt of Milestone Payment from Ferring
13 May 2010
Antares Pharma Reports First Quarter 2010 Financial and Operating Results
6 May 2010
Antares Pharma to Host First Quarter 2010 Earnings Call
4 May 2010
Antares Pharma Announces Receipt of SalesBased Milestone Payment
from TEVA
27 April 2010
ANTARES PHARMA and UMAN PHARMA Enter Collaboration for VIBEXtrade MTX
2 February 2010
Antares Teva Tjet
20 January 2010
Antares Pharma expands Executive Team and appoints Pavan Handa as Senior Vice President of Business Development
11 November 2009
Antares Pharma Enters into License and Asset Purchase Agreements with Ferring
9 November 2009
Antares Pharma Reports Third Quarter 2009 Financial and Operating Results
3 November 2009
Antares Pharma to Present at the Merriman Investor Summit 2009
2 November 2009
Antares Pharma to Host Third Quarter 2009 Earnings Call
27 October 2009
Antares Pharma to Present at the 20th Annual Oppenheimer Healthcare Conference
3 September 2009
Antares Pharma, Inc to Present at Rodman Renshaw 11th Annual Healthcare Conference
25 August 2009
Antares Pharma Announces Launch of Tjet NeedleFree Injector System by Marketing Partner Teva
14 August 2009
Antares Pharma Regains NYSE Amex Listing Compliance
13 August 2009
Antares Pharma Reports Second Quarter 2009 Financial and Operating Results
12 August 2009
Antares Pharma Welcomes Eamonn P Hobbs to Board of Directors
4 August 2009
Antares Pharma to Host Second Quarter 2009 Earnings Call
3 August 2009
Antares Pharma, INC to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference
30 July 2009
Antares Pharma Receives Payment from Teva for Commercial Development of VibexTM AutoInjector Product
29 July 2009
Antares Pharma Announces Closing of Securities Offering
28 July 2009
Antares Pharma, Inc to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference
24 July 2009
Antares Pharma Announces Pricing of Securities Offering
8 July 2009
Antares Pharma Promotes Robert F Apple, Dr Kaushik Dave and Dr Peter Sadowski
17 June 2009
Antares Pharma Announces Partners Update of LibiGelR Safety Study
8 June 2009
Antares Pharma, Inc to Present at 8th Annual Needham Life Sciences Conference
5 June 2009
Antares Pharma, Inc to Present at Noble Financials Fifth Annual Equity Conference
4 June 2009
Antares Pharma Receives NYSE Amex Notification
15 May 2009
Antares Pharma and Population Council Announce Preliminary Positive Phase 2 Trial Results
13 May 2009
Antares Pharma Reports First Quarter 2009 Financial and Operating Results
29 April 2009
Antares Pharma to Host First Quarter 2009 Earnings Call
27 March 2009
Antares Pharma Announces Going Concern Qualification
26 March 2009
Antares Pharma Reports Ferring Pharmaceuticals Receives Frost and Sullivan Human Growth Hormone Competitive Strategy Leadership Award for Zomajet Needle Free Injection
25 March 2009
Antares Pharma Reports Fourth Quarter and Year End 2008 Financial and Operating Results
10 March 2009
Antares Pharma to Host Fourth Quarter and YearEnd 2008 Earnings Call
9 March 2009
Antares to Present at Cowen and Company 29th Annual Healthcare Conference
22 January 2009
Antares Pharma Receives Milestone Payment from Teva for Pen Injector Device Filing
6 January 2009
Antares Pharma Receives Milestone payment and Additional Patent Related to Elestrin R
24 November 2008
Antares Pharma and Population Council Announce Initiation of Phase II Clinical Trial for a Novel Contraceptive ATD Gel
13 November 2008
Antares Pharma Reports Recent Developments and Third Quarter 2008 Financial results
5 November 2008
Antares Announces Additional Regulatory Approvals in Europe and Australia for its NeedleFree Injection Device
13 October 2008
Antares Pharma Appoints Dr Leonard S Jacob as Chairman of the Board
13 October 2008
Antares Pharma Appoints Paul K Wotton, Ph D as President and Chief Executive Officer
3 September 2008
Antares Pharma Enters Into a Feasibility Development Agreement woth Dr Reddys Laboratories, Inc for an Enhanced Dermatology Product Utilizing the ATD Gel Platform
14 August 2008
Antares Pharma Reports Second Quarter Financial Results
5 August 2008
Antares Pharma to Report 2008 Second Quarter Financial Results on August 14, 2008
29 July 2008
Antares Pharma and Teva Announce Filing of SNDA for NeedleFree Injector with Human Growth Hormone
17 July 2008
Antares Pharma to present at the BMO Capital Markets Healthcare Conference
7 July 2008
Antares Pharma appoints Paul Wotton, Ph D as President and Chief Operating Officer
7 July 2008
Antares Pharma appoints Paul Wotton, Ph D as President and Chief Operating Officer
4 June 2008
Antares Receives a Notice of Allowance for US Patent Covering Anturol TM
15 May 2008
Antares Pharma Reports First Quarter 2008 Financial and Operating Results
6 May 2008
Antares Pharma to REport 2008 First Quarter Financial Results on May 15th, 2008
15 April 2008
Antares Pharmas Partner to Initiate Phase II Trial for CNS Therapy in Q4 2008
7 April 2008
Antares Pharma Announces Issuance of Key Patent Covering ATDTM Technology
26 March 2008
Antares Pharma Reports Fourth Quarter and Year End 2007 Financial and Operating Results 2007 Total Revenue and Product Revenue Increased 84 and 46
10 March 2008
Antares Pharma to Report 2007 Results on March 26, 2008
4 March 2008
Antares Pharma Appoints Kaushik J Dave, PhD, RPh,MBA as Vice President of Clinical and Regulatory Affairs
12 February 2008
Antares Receives Positive Guidance for European Registration Testosterone ATDTM Gel Registration Plan Clarified by EMEA
5 February 2008
Antares Pharma to Present at BIO CEO Investor Conference 2008
7 January 2008
Antares Pharma Develops NOvel Pen Injector under New Agreement with TEVA Pharmaceuticals Exclusive License, Development and Supply Agreement
19 December 2007
Antares Receives Milestone Payment Additional Potential of 10 Million in Sales Based Milestones
28 November 2007
Antares Pharma and Population Council Announce Phase I Results First Transdermal Contraceptive Gel Contains Nestorone R
28 November 2007
Antares Pharma to Present at BMO Capital Markets Focus on Healthcare Conference
13 November 2007
Antares Pharma Reports Third Quarter 2007 Financial Results and Operating Progress
29 October 2007
Antares Pharma to Present at Acumen BioFin Rodman Renshaw 9th Annual Healthcare Conference
22 October 2007
Antares Pharma Doses First Patients in Pivotal Trial of Anturol TM
16 October 2007
Antares Product Development Wins 2007 Innovative BioPartnering Award Treating a Significant CNS Disorder
11 October 2007
Antares Executes First Easy Tec TM Life Extension Development and License Agreement
2 October 2007
Antares Reports Product Progress in Growing Womens Health Portfolio
26 September 2007
Antares Pharma to Present at BIO Investor Forum 2007
20 September 2007
Antares Pharma to Present at William Blair SmallCap Growth Stock Conference
17 September 2007
Antares Pharma to Present at UBS Global LIfe Sciences Conference
23 August 2007
Antares Announces Initiation of Pivotal Trial for Anturol TM for the Treatment of Overactive Bladder
13 August 2007
Antares Pharma Reports Second Quarter 2007 Financial and Operating Results
25 July 2007
Antares Reaches Agreement with FDA on Special Protocol Assessment for Pivotal Trial of Anturol TM
19 July 2007
Antares Announces Worldwide Development and License Agreement with Jazz Pharmaceuticals
10 July 2007
Antares Pharma Announces Closing of 16 Million Private Placement
29 June 2007
Antares Pharma Announces Agreement to Raise 15 Million in a Private Placement
13 June 2007
Antares Pharma Announces Commercial Launch of its First Gel Based Pharmaceutical Product
30 May 2007
Antares and the Population Council Initiate Phase I Clinical Study with Innovative LowDose Contraceptive
17 May 2007
Antares Pharma Reports First Quarter 2007 Financial Results
8 May 2007
Antares Pharma to Present at Friedman, Bilings Ramsey Co 2007 Growth Conference
19 April 2007
Antares Pharma Announces Positive Results from Application Site Study for AnturolR
11 April 2007
Antares Pharma Announces Issuance of New Broad Patent Covering Multiple ATDTM Gel Formulations including AnturolR, Elestrin TM and LibiGelR
27 March 2007
Antares Pharma Reports Fourth Quarter and Year End 2006 Financial Results
26 March 2007
Antares Receives 175 Milestone Payment
28 February 2007
Antares Pharma Secures 10MM Credit Facility
7 February 2007
Antares Pharma Announces Allowance for Newest ATD Gel Patent
17 January 2007
Antares Pharma Announces Leonard SJacob MD, PhD to the Companys Board of Directors
2 January 2007
Antares ATD TM Formulation Enters Phase III Study